Effect of valsartan on angiotensin II- and vasopressin-degrading activities in the kidney of normotensive and hypertensive rats

Hormone and Metabolic Research

Volumn 33, Issue 9, 2001, Pages 559-563

  Prieto, I ^a   Martinez J M ^a   Hermoso, F ^a   Ramirez M J ^a   de Gasparo, M ^b   Vargas, F ^a   Alba, F ^a   Ramirez M ^a  

^a UNIVERSITY OF JAÉN   (Spain)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cystinyl Aminopeptidase; Glutamyl Aminopeptidase; Kidney; Renovascular Hypertension; Valsartan

Indexed keywords

AMINOPEPTIDASE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; VALSARTAN; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVITY; KIDNEY CORTEX; KIDNEY MEDULLA; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RENOVASCULAR HYPERTENSION;

AMINOPEPTIDASES; ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; ARGININE VASOPRESSIN; BLOOD PRESSURE; CYSTINYL AMINOPEPTIDASE; DRINKING; GLUTAMYL AMINOPEPTIDASE; HYPERTENSION, RENOVASCULAR; KIDNEY; MALE; PLACEBOS; RATS; RATS, WISTAR; TETRAZOLES; VALINE;

ANIMALIA;

EID: 0034808374     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-17207     Document Type: Article

References (15)

1. Valsartan: Preclinical and clinical profile of an antihypertensive angiotensin-II antagonist
2. Neuropeptides in blood pressure control
3. Sex differences and age-related changes in human serum aminopeptidase A activity
4. Kidney aminopeptidase A and hypertension, part II. Effects of angiotensin II
5. Rat kidney glutamyl aminopeptidase (aminopeptidase A): Molecular identity and cellular localization
6. An aminopeptidase activity from porcine kidney that hydrolyzes oxytocin and vasopressin: Purification and partial characterization
7. Activities of aminopeptidases in a rat saline model of volume hypertension
8. Renal immunocytochemical distribution and pharmacological properties of the dual angiotensin II/AVP receptor
9. Renal aminopeptidase activities in animal models of hypertension
10. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects
11. Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide
12. Pathophysiology of renovascular hypertension
13. Differential regulation of renal angiotensin subtype AT1A and AT2 receptor protein in rats with angiotensin-dependent hypertension
14. Vascular vasopressin receptors in renal hypertensive rats
15. Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats